Chronic Myelogenous Leukemia

  • K. J. Finiewicz


The first cases of chronic myelogenous leukemia (CML) were described in 1845 by Bennett, then Craigie and Virchow. This was followed by decades of studies detailing the histologic and clinical features of CML. The discovery of the Philadelphia chromosome (Ph chromosome) by Nowell and Hungerford in 1960 marked the beginning of a new era in studying the pathogenesis of this disease on the molecular level [1]. After chromosome banding techniques became available, Rowley demonstrated that the shortening of chromosome 22 observed by Nowell is not a result of deletion but, rather, a translocation between chromosomes 9 and 22, t(9;22) [2]. Subsequently, the chimeric gene encoded by t(9;22), bcr-abl, has been defined and cloned [3]. Increasing understanding of the molecular biology of CML and the pivotal role of the bcrabl in the pathogenesis of CML recently culminated in a development of the bcr-abl inhibitor, namely imatinib mesylate (Gleevec, STI-571) [4]. As a results of these events, CML became the first human neoplasm in which the rationally designed therapeutic agent to target the carcinogenic pathway demonstrated clinical efficacy.


Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Imatinib Mesylate Chronic Myeloid Leukemia Patient Cytogenetic Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nowell PC, Hungerford DA (1960) Chromosome studies in normal and leukemic human leukocytes. J Natl Cancer Inst 25:85–109PubMedGoogle Scholar
  2. 2.
    Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293PubMedCrossRefGoogle Scholar
  3. 3.
    Heisterkamp N, Stam K, Groffen J et al (1985) Structural organization of the bcr gene and its role in the Ph translocation. Nature 315:758–761PubMedCrossRefGoogle Scholar
  4. 4.
    Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med:344:1038–1042CrossRefGoogle Scholar
  5. 5.
    Melo JV (1996) The diversity of the BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384PubMedGoogle Scholar
  6. 6.
    Gotoh A, Broxmeyer HE (1997) The function of BCR/ABL and related oncogenes. Curr Opin Hematol 4:3–11PubMedCrossRefGoogle Scholar
  7. 7.
    Pane F, Frigeri F, Sindona M et al (1996) Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410–2414PubMedGoogle Scholar
  8. 8.
    Cervantes F, Colomer D, Vives-Corrons JL et al (1996) Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia 10(7):1241–1243PubMedGoogle Scholar
  9. 9.
    Faderl S, Talpaz M, Estrov Z et al (1999) The biology of chronic myeloid leukemia. New Engl J Med 341:164–172PubMedCrossRefGoogle Scholar
  10. 10.
    Bernstein R (1988) Cytogenetics of chronic myelogenous leukemia. Semin Hematol 25:20–34PubMedGoogle Scholar
  11. 11.
    Majlis A, Smith TL, Talpaz M et al (1996) Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14:196–203PubMedGoogle Scholar
  12. 12.
    Sakuri M, Sandberg AA (1976) The chromosomes and causation of human cancer and leukemia. XVIII. The missing Y in acute myeloid leukemia (AML) and Ph-positive chronic myelocytic leukemia (CML). Cancer 38:762–768CrossRefGoogle Scholar
  13. 13.
    Wiedemann LM, Karhi KK, Shivji M et al (1988) The correlation of breakpoint cluster region rearrangement and P210Phl/abl expression with morphological analysis of Phnegative chronic myeloid leukemia and other myeloproliferative diseases. Blood 71:349–355PubMedGoogle Scholar
  14. 14.
    Cortes J, Talpaz M, O’Brien et al (1995) Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region: long term follow-up results. Cancer 75:464–470PubMedCrossRefGoogle Scholar
  15. 15.
    Sokal JE, Baccarani M, Russo D et al (1988) Staging and prognosis in chronic myelogenous leukemia. Seminars in Hematology 25:49–61PubMedGoogle Scholar
  16. 16.
    Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation (1999) Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol 17:1858–1868Google Scholar
  17. 17.
    Hehlmann R, Ansari H, Hasford J et al (1997) Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal’s index and a new score. German Chronic Myeloid Leukaemia Study Group. Br J Haematol 97:76–85PubMedCrossRefGoogle Scholar
  18. 18.
    Hasford J, Pfirrman M, Hehlmann R et al (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia. J Natl Cancer Inst 90:850–858PubMedCrossRefGoogle Scholar
  19. 19.
    Kantarjian HM, Smith TL, O’Brian S et al (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to IFN-α therapy. Ann Intern Med 122:254–261PubMedGoogle Scholar
  20. 20.
    Gratwohl A, Hermans J, Goldman JM et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow. Transplantation. Lancet 352:1087–1092PubMedCrossRefGoogle Scholar
  21. 21.
    Radich JP, Gehly G, Gooley T et al (1995) Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85:2632–2638PubMedGoogle Scholar
  22. 22.
    Lin F, van Rhee F, Goldman JM, Cross NCP (1996) Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87:4473–4478PubMedGoogle Scholar
  23. 23.
    Hochhaus A, Reiter A, Saubele S et al (2000) Molecular heterogeneity in complete cytogenetic responders after interferon therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95:62–66PubMedGoogle Scholar
  24. 24.
    Faderl S, Talpaz M, Kantarjian HM, Estrov Z (1999) Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 93:2755–2759PubMedGoogle Scholar
  25. 25.
    Hehlmann R, Heimpel H, Hasford J et al (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia. Prolongation of survival by hydroxyurea. Blood 82:398–407PubMedGoogle Scholar
  26. 26.
    Chronic Myeloid Leukemia Trialists’ Collaborative Group (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616–1620CrossRefGoogle Scholar
  27. 27.
    Goldman JM, Szydlo R, Horowitz MM et al (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235–2238PubMedGoogle Scholar
  28. 28.
    Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia. N Engl J Med 330:820–823CrossRefGoogle Scholar
  29. 29.
    Hehlmann R, Heimpel H, Hasford J et al (1994) Randomized comparison of interferon-alfa with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064–4077PubMedGoogle Scholar
  30. 30.
    Allan NC, Richards SM, Shepherd PC et al (1995) UK Medical Research Council randomized multicenter trial of interferon-αn 1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 345:1392–1397PubMedCrossRefGoogle Scholar
  31. 31.
    Ohnishi K, Ohno R, Tomonaga M et al (1995) A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. The Kouseisho Leukemia Study Group. Blood 86:906–916PubMedGoogle Scholar
  32. 32.
    The Benelux CML Study Group (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-2b for chronic myeloid leukemia. Blood 91:2713–2721Google Scholar
  33. 33.
    Kantarjian HM, O’B rien S, Anderlini P, Talpaz M (1996) Treatment of myelogenous leukemia: current status and investigational options. Blood 87:3069–3081PubMedGoogle Scholar
  34. 34.
    Freund M, von Wussow P, Dietrich H et al (1989) Recombinant human interferon alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350–356PubMedCrossRefGoogle Scholar
  35. 35.
    Schofield JR, Robinson WA, Murphy JR et al (1994) Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736–744PubMedGoogle Scholar
  36. 36.
    Kantarjian HM, Giles FJ, O’B rien SM et al (1998) Clinical course and therapy of chronic myelogenous leukemia with interferon alpha and chemotherapy. Hematol Oncol Clin North Am 12:31–80PubMedCrossRefGoogle Scholar
  37. 37.
    Kantarjian HM, Keating M, Estey E et al (1992) Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-a and low dose cytarabine. J Clin Oncol 10:772–778PubMedGoogle Scholar
  38. 38.
    Guilhot F, Chastaing C, Michallet M et al (1997) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223–229PubMedCrossRefGoogle Scholar
  39. 39.
    Tura S (1998) Cytarabine increases karyotypic response in alpha-IFN-treated chronic myeloid leukemia patients: results of a national prospective randomized trial (abstract no. 1299). Blood 92:317AGoogle Scholar
  40. 40.
    Lindauer M, Domkin D, Dohner H et al (1999) Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukaemia. Br J Haematol 106:1013–1019PubMedCrossRefGoogle Scholar
  41. 41.
    Mahon FX, Faberes C, Pueyo S et al (1998) Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-a. Blood 92:4059–4065PubMedGoogle Scholar
  42. 42.
    Sacchi S, Kantarjian HM, Smith TL et al (1998) Early treatment decisions with interferon-alfa therapy in early chronic phase chronic myelogenous leukemia. J Clin Oncol 16:882–889PubMedGoogle Scholar
  43. 43.
    Silver RT, Woolf SH, Hehlmann R et al (1999) An evidencebased analysis of the effect of busulphan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517–1536PubMedGoogle Scholar
  44. 44.
    Druker BJ, Lydon LB (2000) Lessons learned from the development of an Abl kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7PubMedCrossRefGoogle Scholar
  45. 45.
    Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566PubMedCrossRefGoogle Scholar
  46. 46.
    Druker BJ, Talpaz M, Resta D et al (2001) Clinical efficacy and safety of an specific ABL-specific tyrosine kinase inhibitor as a targeted therapy for chronic myeloid leukemia. N Engl J Med 344:1031–1037PubMedCrossRefGoogle Scholar
  47. 47.
    Imatinib package insert (2001) Novartis Pharmaceuticals, East Hanover, New JerseyGoogle Scholar
  48. 48.
    Novartis press releaseGoogle Scholar
  49. 49.
    Topaly J, Zeller WJ, Freuhauf S et al (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342–347PubMedCrossRefGoogle Scholar
  50. 50.
    Thiesing JT, Ohno-Jones S, Kolibaba KS et al (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl positive cells. Blood 96:3195–3199PubMedGoogle Scholar
  51. 51.
    Kano Y, Akatsu M, Tsunoda S et al (2001) In vitro cytotoxic effects of tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999–2007PubMedCrossRefGoogle Scholar
  52. 52.
    Horowitz MM, Rowlings PA, Passweg JR (1996) Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17:S5–S6PubMedGoogle Scholar
  53. 53.
    Van Rhee F, Szydlo RM, Hermans J et al (1997) Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European ernat ion alBo ne Marrow TransplantRegistry. Bone Marrow Transplant 20:553–560PubMedCrossRefGoogle Scholar
  54. 54.
    Appelbaum FR (2001) Perspectives on the future of chronic myeloid leukemia treatment. Seminars Oncol 38[Suppl 8]: 35–42Google Scholar
  55. 55.
    Clift RA, Appelbaum FR, Thomas ED (1993) Treatment of chronic myeloid leukemia by Marrow Transplantation. Blood 82:1954–1956PubMedGoogle Scholar
  56. 56.
    Hansen JA, Gooley TA, Martin PJ et al (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New Engl J Med 338:962–968PubMedCrossRefGoogle Scholar
  57. 57.
    Devergie A, Reiffers J, Vernant JP et al (1990) Lon-term follow-up after transplantation for chronic myelogenous leukemia. Factors associated with relapse. Bone Marrow Transplant 5:379–386PubMedGoogle Scholar
  58. 58.
    Lee SJ (2000) Chronic myelogenous leukemia. Br J Haematol 111:993–1009PubMedCrossRefGoogle Scholar
  59. 59.
    Holler E, Schleuning M, Ledderose G et al (1995) IFNalpha prior to allogeneic BMT in patients with chronic myelogenous leukemia (abstract no. 383). Ann Hematol 73:96AGoogle Scholar
  60. 60.
    Hehlmann R, Hochhaus A, Kolb HJ et al (1999) Interferonalpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94:3668–3677PubMedGoogle Scholar
  61. 61.
    McGlave P, Bartsch G, Anasetti C et al (1993) Unrelateddonor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 81:543–550PubMedGoogle Scholar
  62. 62.
    Devergie A, Apperley JF, Labopin M et al (1997) European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:11–19PubMedCrossRefGoogle Scholar
  63. 63.
    Sasazuki T, Juju T, Morishima Y et al (1998) Effect of matching of class I alleles on clinical outcome after transplantation of hematopoietic stem cells from unrelated donors. N Engl J Med 339:1177–1185PubMedCrossRefGoogle Scholar
  64. 64.
    McGlave P, Kollman C, Shu XO et al (1996) The first 1000 unrelated donor transplants for CML: lessons from the National Marrow Donor Program (NMDP) experience (abstract no. 1922). Blood 88:483AGoogle Scholar
  65. 65.
    Slavin S, Nagler A, Naparstek E et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763PubMedGoogle Scholar
  66. 66.
    Bacigalupo A (2000) Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 25:803–805PubMedCrossRefGoogle Scholar
  67. 67.
    Porter DL, Roth MS, McGarigle C et al (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100–106PubMedCrossRefGoogle Scholar
  68. 68.
    Porter DL, Collins RH, Hardy C et al (2000) Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood, 95: 1214–1221PubMedGoogle Scholar
  69. 69.
    Dazzi F, Szydlo RM, Craddock C et al (2000) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95:67–71PubMedGoogle Scholar
  70. 70.
    Higano CS, Chielens D, Raskind W et al (1997) Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 90: 2549–2554PubMedGoogle Scholar
  71. 71.
    Gale RP, Hehlmann R, Zhang M-J et al (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91: 1810–1819PubMedGoogle Scholar
  72. 72.
    Lee SJ, Kuntz KM, Horowitz MM et al (1997) Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Int Med 127: 1080–1088PubMedGoogle Scholar
  73. 73.
    Talpaz M, Silver RT, Druker BJ et al (2000) A Phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase (abstract no. 2012). Blood 96:469AGoogle Scholar
  74. 74.
    Derderian PM, Kantarjian HM, Talpaz M et al (1993) Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94:69–74PubMedCrossRefGoogle Scholar
  75. 75.
    Sacchi S, Kantarjian HM, O’B rien S et al (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86: 2632–2641PubMedCrossRefGoogle Scholar
  76. 76.
    Kantarjian HM, Keating MJ, Talpaz et al (1987) Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 83:445–454PubMedCrossRefGoogle Scholar
  77. 77.
    Hehlmann R (2000) Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 14:1560–1562PubMedCrossRefGoogle Scholar
  78. 78.
    Dann EJ, Anastasi J, Larson RA (1998) High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol 16:1498–1504PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • K. J. Finiewicz

There are no affiliations available

Personalised recommendations